Research programme: atherosclerosis/lipid metabolism disorders therapeutics - AbbVie/Genfit
Alternative Names: SOL-02Latest Information Update: 04 Nov 2017
At a glance
- Originator Genfit; Laboratoires Fournier
- Developer AbbVie; Genfit
- Class
- Mechanism of Action Cytoplasmic and nuclear receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Lipid metabolism disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Atherosclerosis in France
- 04 Nov 2017 No recent reports of development identified for preclinical development in Lipid-metabolism-disorders in France
- 22 Jan 2013 This programme is still in active development